MetaCap

Kymera Therapeutics (KYMR) vs Vaxcyte (PCVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kymera Therapeutics (KYMR) has outperformed Vaxcyte (PCVX) over the past year, gaining 74.6% versus a gain of 15.9%. Over five years, PCVX leads with a +178.9% price change compared with +114.4% for KYMR. Kymera Therapeutics is the larger company by market cap ($9.84 billion vs $8.77 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYMR+74.61%PCVX+15.93%
+116%+50%-16%
Nov 21, 20251 yearNov 20, 2026
KYMR+87.50%PCVX+143.90%
+435%+164%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYMR versus PCVX key metrics
MetricKYMRPCVX
Share price$115.31$55.39
Market cap$9.84B$8.77B
1-day change-3.42%-5.09%
YTD return+48.19%+20.05%
1-year return+74.61%+15.93%
5-year return+114.37%+178.90%
EPS (TTM)$-3.64$-8.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$39.21M—
Revenue growth (YoY)-16.70%—
Net income (latest FY)$-311.35M$-766.63M
Gross margin0.00%—
Operating margin-891.07%—
Net margin-794.04%—
52-week high$142.92$90.75
52-week low$63.69$42.40
Distance from 52-week high-19.32%-38.96%
Analyst consensusstrong_buynone
Avg. price target upside+25.94%+110.15%
Average volume852.46K2.19M
Shares outstanding85.37M158.30M
Employees285507
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KYMR has outperformed PCVX by 58.7 percentage points over the past year.

About Kymera Therapeutics

KYMR stock →

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 285 employees

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

KYMR vs PCVX FAQ

Which is bigger, Kymera Therapeutics or Vaxcyte?

Kymera Therapeutics (KYMR) is larger, with a market capitalization of $9.84B compared with $8.77B for Vaxcyte (PCVX).

Which stock has performed better over the past year, KYMR or PCVX?

KYMR returned +74.61% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are Kymera Therapeutics and Vaxcyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons